These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38258766)
1. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Velmurugan H; Venkatesan S; Meles HN; Neelambaram K; Thangaraju P Infect Disord Drug Targets; 2024; 24(6):e220124225835. PubMed ID: 38258766 [TBL] [Abstract][Full Text] [Related]
2. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant August B; Matlob A; Kale-Pradhan PB Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. Findlay J; Poirel L; Bouvier M; Nordmann P J Glob Antimicrob Resist; 2022 Sep; 30():445-450. PubMed ID: 35618210 [TBL] [Abstract][Full Text] [Related]
8. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Petropoulou D; Siopi M; Vourli S; Pournaras S Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562 [TBL] [Abstract][Full Text] [Related]
9. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Moussa SH; Shapiro AB; McLeod SM; Iyer R; Carter NM; Tsai Y-K; Siu LK; Miller AA Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066523. PubMed ID: 37843305 [No Abstract] [Full Text] [Related]
13. In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex. McLeod SM; Carter NM; Bradford PA; Miller AA Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116344. PubMed ID: 38735147 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359 [TBL] [Abstract][Full Text] [Related]
16. Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam-durlobactam holds promise for therapeutic intervention. Naha A; Vijayakumar S; Lal B; Shankar BA; Chandran S; Ramaiah S; Veeraraghavan B; Anbarasu A J Cell Biochem; 2021 Dec; 122(12):1946-1957. PubMed ID: 34597421 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China. Yang Q; Xu Y; Jia P; Zhu Y; Zhang J; Zhang G; Deng J; Hackel M; Bradford PA; Reinhart H J Antimicrob Chemother; 2020 Jul; 75(7):1833-1839. PubMed ID: 32306049 [TBL] [Abstract][Full Text] [Related]
18. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex. O'Donnell JP; Bhavnani SM Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534 [TBL] [Abstract][Full Text] [Related]
20. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. McLeod SM; Carter NM; Huband MD; Traczewski MM; Bradford PA; Miller AA J Clin Microbiol; 2024 Jan; 62(1):e0122823. PubMed ID: 38095417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]